Luspatercept for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Jul 2023: Trial registered, NCT05949684
  2. 24 Oct 2023: Trial started, NCT05949684

The trials

NCT05949684: ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

State
Under way
Phase
Phase 3
People
402 taking part
Started
24 Oct 2023
Primary completion
24 Mar 2028
Arms
Luspatercept
Results
None posted
  1. 18 Jul 2023: Trial registered
  2. 24 Oct 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.